With 2.99 million shares changed hands, the volume of the stock remained heavier than its average volume of 2.96 million shares. During the session, the Diagnostics & Research company that operates in wider Healthcare sector, reached to the highest price of $243.15 whereas the lowest price it dropped to was $238.07. The 52-week range on DHR shows that it touched its highest point at $281.70 and its lowest point at $222.53 during that stretch. It currently has a 1-year price target of $283.92. With its current market cap of 172.70 billion, DHR has annualized dividend of $1.08 while the current yield stands at 0.45%. Beta for the stock currently stands at 0.84.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of DHR was up-trending over the past week, with a rise of 4.11%, but this was up by 4.93% over a month. Three-month performance dropped to -11.05% while six-month performance fell -0.29%. The stock gained 3.83% in the past year, while it has gained 4.16% so far this year. A look at the trailing 12-month EPS for DHR yields 5.24 with Next year EPS estimates of 8.26. For the next quarter, that number is 2.15. This implies an EPS growth rate of -1.15% for this year and 10.31% for next year. EPS is expected to grow by 5.87% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 11.31%.
Float and Shares Shorts:
At present, 722.20 million DHR shares are outstanding with a float of 692.96 million shares on hand for trading. On 2024-12-13, short shares totaled 5.73 million, which was 79.00001 higher than short shares on 1731628800. In addition to Mr. Steven M. Rales as the firm’s Co-Founder & Chairman, Mr. Rainer M. Blair serves as its President, CEO & Director.
Institutional Ownership:
Through their ownership of 0.81575996 of DHR’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-27, DHR reported revenue of $5798000000.0 and operating income of $958000000.0. The EBITDA in the recently reported quarter was $1552000000.0 and diluted EPS was $1.12.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for DHR since 20 analysts follow the stock currently. There are 14 analysts who recommend BUY ratings, while 1 suggest SELL ratings. Of the remaining analysts, 5 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With DHR analysts setting a high price target of 315.0 and a low target of 255.0, the average target price over the next 12 months is 284.4269. Based on these targets, DHR could surge 31.74% to reach the target high and rise by 6.65% to reach the target low. Reaching the average price target will result in a growth of 18.96% from current levels.
Analysts have provided yearly estimates in a range of $7.54158 being high and $7.47166 being low. For DHR, this leads to a yearly average estimate of $7.49164.
